AB
PRME icon

Amalgamated Bank’s Prime Medicine PRME Stock Holding History

Amalgamated Bank’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,126
Closed -$11K – 2524
2025
Q4 		$11K Buy
3,126
+1,169
+60% +$5.2K ﹤0.01% 2387
2025
Q3 		$11K Hold
1,957
– – ﹤0.01% 2429
2025
Q2 		$5K Hold
1,957
– – ﹤0.01% 2778
2025
Q1 		$4K Buy
1,957
+610
+45% +$1.56K ﹤0.01% 2742
2024
Q4 		$4K Hold
1,347
– – ﹤0.01% 2801
2024
Q3 		$5K Hold
1,347
– – ﹤0.01% 2772
2024
Q2 		$7K Hold
1,347
– – ﹤0.01% 2638
2024
Q1 		$9K Sell
1,347
-4,266
-76% -$32.4K ﹤0.01% 2493
2023
Q4 		$50K Sell
5,613
-401
-7% -$3.09K ﹤0.01% 2251
2023
Q3 		$57K Buy
6,014
+1,262
+27% +$16.4K ﹤0.01% 2201
2023
Q2 		$70K Buy
4,752
+3,488
+276% +$48.7K ﹤0.01% 2188
2023
Q1 		$16K Sell
1,264
-303
-19% -$4.94K ﹤0.01% 2723
2022
Q4 		$29K Buy
+1,567
New +$28.3K ﹤0.01% 2637

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Amalgamated Bank's PRME Position: Q1 2026 in Review

Amalgamated Bank sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 3,126 shares — an estimated $11K sold.

Amalgamated Bank first reported a position in PRME in Q4 2022 and held it in 13 quarters. The position peaked at $70K in Q2 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Amalgamated Bank reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 3,126 Prime Medicine shares in Q1 2026, an estimated $11K.
  • Amalgamated Bank first reported a position in Prime Medicine in Q4 2022 and held it in 13 quarters.
  • Amalgamated Bank's Prime Medicine position peaked at $70K in Q2 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.